1061 Stock Overview

An investment holding company, develops, manufactures, distributes, and sells bio-pharmaceutical products in the People’s Republic of China, Hong Kong, and internationally. More details

1061 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	4/6

Rewards

Price-To-Earnings ratio (6x) is below the Hong Kong market (10x)

Earnings have grown 0.01% per year over the past 5 years

Risk Analysis

Unstable dividend track record

My Notes

Capture your thoughts, links and company narrative

Essex Bio-Technology Limited Competitors

Shandong Boan Biotechnology

SEHK:6955

HK$4.7b

Uni-Bio Science Group

SEHK:690

HK$370.2m

TOT BIOPHARM International

SEHK:1875

HK$1.2b

HBM Holdings

SEHK:2142

HK$981.5m

Price History & Performance

Summary of share price highs, lows and changes for Essex Bio-Technology
Historical stock prices
Current Share Price	HK$2.78
52 Week High	HK$3.10
52 Week Low	HK$1.96
Beta	0.14
1 Month Change	5.30%
3 Month Change	23.01%
1 Year Change	18.80%
3 Year Change	-42.68%
5 Year Change	-55.09%
Change since IPO	180.81%

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Oct 09

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Oct 09

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Shareholder Returns

	1061	HK Biotechs	HK Market
7D	-3.8%	-5.2%	-2.2%
1Y	18.8%	-5.3%	18.3%

Return vs Industry: 1061 exceeded the Hong Kong Biotechs industry which returned -5.3% over the past year.

Return vs Market: 1061 matched the Hong Kong Market which returned 18.3% over the past year.

Price Volatility

Is 1061's price volatile compared to industry and market?
1061 volatility
1061 Average Weekly Movement	5.5%
Biotechs Industry Average Movement	11.0%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.7%
10% least volatile stocks in HK Market	4.1%

Stable Share Price: 1061 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1061's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1990	1,459	Haizhou Fang	www.essexbio.com

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells bio-pharmaceutical products in the People’s Republic of China, Hong Kong, and internationally. The company operates through Ophthalmology and Surgical segments. It researches and develops therapeutic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration.

Essex Bio-Technology Limited Fundamentals Summary

How do Essex Bio-Technology's earnings and revenue compare to its market cap?
1061 fundamental statistics
Market cap	HK$1.58b
Earnings (TTM)	HK$262.89m
Revenue (TTM)	HK$1.62b

6.0x

P/E Ratio

1.0x

P/S Ratio

Is 1061 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1061 income statement (TTM)
Revenue	HK$1.62b
Cost of Revenue	HK$165.38m
Gross Profit	HK$1.45b
Other Expenses	HK$1.19b
Earnings	HK$262.89m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.46
Gross Margin	89.78%
Net Profit Margin	16.24%
Debt/Equity Ratio	15.2%

How did 1061 perform over the long term?

See historical performance and comparison

Dividends

4.3%

Current Dividend Yield

23%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 20:50
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Essex Bio-Technology Limited is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Xiao Wei Lin	Everbright Securities Co. Ltd.
null null	Guoyuan Securities (HK) Ltd
Stella Xing	Nomura Securities Co. Ltd.

1061 Stock Overview

Rewards

Risk Analysis

Essex Bio-Technology Limited Competitors

SEHK:6955

HK$4.7b

SEHK:690

HK$370.2m

SEHK:1875

HK$1.2b

SEHK:2142

HK$981.5m

Price History & Performance

Recent News & Updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 19%

First half dividend increased to HK$0.06

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

First half 2024 earnings released: EPS: HK$0.28 (vs HK$0.30 in 1H 2023)

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 19%

First half dividend increased to HK$0.06

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

First half 2024 earnings released: EPS: HK$0.28 (vs HK$0.30 in 1H 2023)

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)